Source-grounded facts extracted from Olema Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Olema Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026 was $53.1 million, as compared to $30.4 million for the quarter ended Marc.
“On May 12, 2026, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended March 31, 2026.”
Olema Pharmaceuticals, Inc. entered into Lease with KR Oyster Point II, LLC (effective 2026-04-27).
“On April 27, 2026, Olema Pharmaceuticals, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with KR Oyster Point II, LLC, a Delaware limited liability company (the “Landlord”)”
Prakash Raman was appointed as Class II director at Olema Pharmaceuticals, Inc..
“the Board appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026”
Olema Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the quarter and year ended December 31, 2025 was $46.1 million and $162.5 million, respectively.
“On March 16, 2026, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the year ended December 31, 2025.”
Olema Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $31.0 million.
“On May 8, 2024, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended March 31, 2024.”
Olema Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: net income Net loss was $96.7 million.
“Net loss was $26.8 million and $96.7 million for the quarter and year ended December 31, 2023, respectively”
Olema Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2023 results: net income Net loss was $26.8 million.
“Net loss was $26.8 million and $96.7 million for the quarter and year ended December 31, 2023, respectively”
Olema Pharmaceuticals, Inc. entered into ATM Agreement with Cowen and Company, LLC valued at up to $150 million (effective 2024-01-05).
“On January 5, 2024, Olema Pharmaceuticals, Inc., or the Company, entered into a sales agreement, or the ATM Agreement, with Cowen and Company, LLC, or TD Cowen, as sales agent, pursuant to which the Company may offer and sell, from time to time through TD Cowen, at its option, shares of its common stock, par value $0.0001 per share, or the Shares, having an aggregate offering price of up to $150 million.”
Olema Pharmaceuticals, Inc. reported quarter ended September 30, 2023 results: net income $21.5 million.
“Net loss for the quarter ended September 30, 2023, was $21.5 million”
Scott Garland was appointed as Class III Director at Olema Pharmaceuticals, Inc..
“appointed Scott Garland to the Board as a Class III director, effective October 16, 2023”
Olema Pharmaceuticals, Inc. amended Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement with Novartis Institutes for BioMedical Research, Inc. (effective 2023-10-09).
“On October 9, 2023, Olema Pharmaceuticals, Inc. (the “Company”) entered into an Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement (the “Amendment”) with Novartis Institutes for BioMedical Research, Inc. (“Novartis”).”
Olema Pharmaceuticals, Inc. entered into Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the "Bank") valued at up to $50 million (effective 2023-09-05).
“On September 5, 2023, the Company entered into a Loan and Security Agreement (the “Loan Agreement”), by and between the Company, as borrower, and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the “Bank”). The Loan Agreement provides for a four-year senior secured Loan facility in an aggregate principal amount of up to $50 million (the “Loan Facility”), of which $25 million will be available upon the receipt by the Company of $100 million in gross proceeds from the Private Placement, and up to $25 million of which may be made available upon approval of the Bank in its discretion.”
Olema Pharmaceuticals, Inc. entered into Purchase Agreement with the purchasers named therein (the "Purchasers") valued at approximately $130 million (effective 2023-09-05).
“On September 5, 2023, Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), which provides for the private placement of 13,211,381 shares (the “Shares”) of the Company’s common stock (the “Common Stock”) at $9.84 per share (such transaction, the “Private Placement”).”
Olema Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2023.
“On August 8, 2023, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended June 30, 2023.”
Olema Pharmaceuticals, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-06-15 meeting.
“Proposal 3— Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results For Against Abstain 30,921,828 10,323 540,055”
Olema Pharmaceuticals, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-06-15 meeting.
“Proposal 2— Advisory Vote on Executive Compensation Final Voting Results For Against Abstain Broker Non-Votes 18,713,603 1,912,571 5,021,093 5,824,939”
Olema Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-06-15 meeting.
“Proposal 1— Election of Directors Final Voting Results Nominees For Withheld Broker Non-Votes Sean P. Bohen, M.D., Ph.D. 23,524,203 2,123,064 5,824,939 Yi Larson 17,980,507 7,666,760 5,824,939 Andrew Rappaport 23,727,247 1,920,020 5,824,939”
Olema Pharmaceuticals, Inc. reported first quarter ended March 31, 2023 results: net income $28.3 million.
“Net loss for the quarter ended March 31, 2023, was $28.3 million”
Olema Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: net income $104.8 million.
“Net loss was $26.2 million and $104.8 million for the quarter and year ended December 31, 2022, respectively”
Olema Pharmaceuticals, Inc. reported the quarter ended December 31, 2022 results: net income $26.2 million.
“Net loss was $26.2 million and $104.8 million for the quarter and year ended December 31, 2022, respectively”
Olema Pharmaceuticals, Inc.: Amended and restated bylaws to update procedures for stockholder nominations regarding Rule 14a-19, update information requirements for director nominations and other business proposals, and update provisions for stockholder meetings (effective 2022-12-15).
“On December 15, 2022, the Board of Directors (the “ Board ”) of Olema Pharmaceuticals, Inc. (the “ Company ”) approved the amendment and restatement of the Bylaws of the Company (the “ Amended and Restated Bylaws ”). The Amended and Restated Bylaws are effective as of December 15, 2022.”
Olema Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: net income $22.7 million.
“Net loss for the quarter ended September 30, 2022, was $22.7 million”
Peter Kushner changed role as Senior Research Fellow and Co-Founder at Olema Pharmaceuticals, Inc..
“On March 10, 2022, Peter Kushner, Ph.D., Chief Scientific Officer (“CSO”) of Olema Pharmaceuticals, Inc. (the “Company”), and the Company agreed that Dr. Kushner would transition from CSO to Senior Research Fellow and Co-Founder, a non-executive role, effective April 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.